MX2009011358A - Derivados de pirimidinona y metodos para su uso. - Google Patents

Derivados de pirimidinona y metodos para su uso.

Info

Publication number
MX2009011358A
MX2009011358A MX2009011358A MX2009011358A MX2009011358A MX 2009011358 A MX2009011358 A MX 2009011358A MX 2009011358 A MX2009011358 A MX 2009011358A MX 2009011358 A MX2009011358 A MX 2009011358A MX 2009011358 A MX2009011358 A MX 2009011358A
Authority
MX
Mexico
Prior art keywords
methods
pyrimidinone derivatives
pyrimidinone
derivatives
gpr119
Prior art date
Application number
MX2009011358A
Other languages
English (en)
Inventor
Samuel Chackalamannil
Jinsong Hao
Hong Liu
Craig D Boyle
Unmesh G Shah
Bernard R Neustadt
Andrew W Stamford
Santhosh Francis Neelamkavil
Joel Harris
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009011358A publication Critical patent/MX2009011358A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a Derivados de Pirimidinona, composiciones caracterizado además porque comprenden un Derivado de Pirimidinona, y métodos de uso de los Derivados de Pirimidinona para tratar o prevenir la obesidad, diabetes, un trastorno metabólico, una enfermedad cardiovascular o un trastorno relacionado con la actividad del receptor 119 acoplado a la proteína G ("GPR119") en un paciente.
MX2009011358A 2007-04-20 2008-04-17 Derivados de pirimidinona y metodos para su uso. MX2009011358A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92545007P 2007-04-20 2007-04-20
US95334207P 2007-08-01 2007-08-01
PCT/US2008/004933 WO2008130581A1 (en) 2007-04-20 2008-04-17 Pyrimidinone derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009011358A true MX2009011358A (es) 2009-11-05

Family

ID=39655056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011358A MX2009011358A (es) 2007-04-20 2008-04-17 Derivados de pirimidinona y metodos para su uso.

Country Status (11)

Country Link
US (1) US20100190687A1 (es)
EP (1) EP2148869A1 (es)
JP (1) JP2010524940A (es)
CN (1) CN102015677A (es)
AR (1) AR066121A1 (es)
CA (1) CA2684633A1 (es)
CL (1) CL2008001126A1 (es)
MX (1) MX2009011358A (es)
PE (1) PE20090151A1 (es)
TW (1) TW200900403A (es)
WO (1) WO2008130581A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008038768A1 (ja) * 2006-09-28 2010-01-28 大日本住友製薬株式会社 二環性ピリミジン構造を有する化合物及びそれを含有する医薬組成物
WO2010095767A1 (en) * 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102234287B (zh) 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN102464661B (zh) * 2010-11-16 2015-04-01 天津药明康德新药开发有限公司 一种5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸乙酯的制备方法
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
JP6211530B2 (ja) 2012-11-19 2017-10-11 武田薬品工業株式会社 含窒素複素環化合物
JP2016222621A (ja) * 2015-06-02 2016-12-28 学校法人九州文化学園 メラニン合成促進組成物
WO2017021805A1 (en) 2015-07-31 2017-02-09 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
RU2720203C1 (ru) 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
JP2020506903A (ja) 2017-01-23 2020-03-05 ファイザー・インク Ｍａｇｌ阻害薬としての複素環式スピロ化合物
CN110452157B (zh) * 2018-12-28 2020-11-03 广州市朗启医药科技有限责任公司 常山酮及其中间体的合成方法
CA3132531A1 (en) * 2019-03-14 2020-09-17 Janssen Sciences Ireland Unlimited Company Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
EP4161643A1 (en) * 2020-06-05 2023-04-12 Pathios Therapeutics Limited N-(phenylaminocarbonyl) tetrahydro-isoquinolines and related compounds as modulators of gpr65
CA3181982A1 (en) * 2020-06-09 2021-12-16 David A. Scott Allosteric egfr inhibitors and methods of use thereof
WO2022053010A1 (en) * 2020-09-11 2022-03-17 Janssen Sciences Ireland Unlimited Company Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
WO2022087011A1 (en) * 2020-10-21 2022-04-28 Aligos Therapeutics, Inc. Bicyclic compounds
US11957683B2 (en) 2021-06-18 2024-04-16 Aligos Therapeutics, Inc. Bicyclic compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264439A (en) * 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
US5449682A (en) * 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
US5240938A (en) * 1991-02-13 1993-08-31 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5409926A (en) * 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
EP1006113A1 (en) * 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
ES2280435T3 (es) * 2000-12-01 2007-09-16 Astellas Pharma Inc. Metodo de exploracion de remedios para la diabetes.
JP2006518763A (ja) * 2003-02-24 2006-08-17 アリーナ ファーマシューティカルズ， インコーポレイテッド グルコース代謝のモジュレーターとしてのフェニル−およびピリジルピペリジン誘導体
EP1951244A4 (en) * 2005-11-22 2010-08-25 Glaxosmithkline Llc CALCILYTIC COMPOUNDS
JPWO2008038768A1 (ja) * 2006-09-28 2010-01-28 大日本住友製薬株式会社 二環性ピリミジン構造を有する化合物及びそれを含有する医薬組成物

Also Published As

Publication number Publication date
EP2148869A1 (en) 2010-02-03
CL2008001126A1 (es) 2008-10-24
PE20090151A1 (es) 2009-02-26
CA2684633A1 (en) 2008-10-30
WO2008130581A1 (en) 2008-10-30
AR066121A1 (es) 2009-07-22
TW200900403A (en) 2009-01-01
US20100190687A1 (en) 2010-07-29
CN102015677A (zh) 2011-04-13
JP2010524940A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
MX2009011358A (es) Derivados de pirimidinona y metodos para su uso.
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
IL193996A0 (en) Neuromedin u receptor agonists and uses thereof
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
SI1957484T1 (sl) Antagonisti glukagonskega receptorja, priprava in terapevtske uporabe
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
MX2009000900A (es) Derivados de imidazolonas sustituidas, preparacion y usos.
HK1158192A1 (en) Piperidine gpcr agonists
MX2009004362A (es) Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk.
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
GB0611907D0 (en) Compounds
JO2747B1 (en) Vehicles
WO2007133983A3 (en) 2-aminobenzimidazoles for treating neurodegenerative diseases